Skip to main content

Advertisement

SpringerLink
Log in

Use of Novel Oral Anticoagulants in Patients With Heart Failure

  • Heart Failure (W Tang, Section Editor)
  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

Pathophysiologically, there is a prothrombotic state evident in heart failure (HF). This is particularly evident within atria in patients whose course of the disease is complicated by concomitant atrial fibrillation (AF). A predisposition for thrombogenesis exists in patients with dilated dysfunctional cardiac chambers, such as those seen in patients with large myocardial infarction, left ventricular (LV) aneurysm or dilated cardiomyopathy. Based on subgroup analyses of recent phase 3 randomized trials, the novel oral anticoagulants are equally effective and safe in AF patients with HF or without HF. This appears to be true regarding both HF with systolic LV dysfunction and with preserved LVEF. However, patients with HF with preserved LVEF with more strict definition (ie, LVEF ≥ 55 %) have not been analyzed specifically. There is no information from clinical trial regarding possible utility of the novel oral anticoagulants in HF patients in sinus rhythm. Further research is required to cover gaps in knowledge on utility of these medications in a substantial proportion of HF patients not included in major clinical trials on novel oral anticoagulants.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Jhund PS, Macintyre K, Simpson CR, Lewsey JD, Stewart S, Redpath A, et al. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation. 2009;119:515–23.

    Article  PubMed  Google Scholar 

  2. Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail. 2011;13:18–28.

    Article  PubMed  Google Scholar 

  3. Lip GY, Piotrponikowski P, Andreotti F, Anker SD, Filippatos G, Homma S, et al. Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the esc heart failure association and the esc working group on thrombosis. Thromb Haemost. 2012;108:1009–22.

    Article  CAS  PubMed  Google Scholar 

  4. Uretsky BF, Thygesen K, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (atlas) trial. Circulation. 2000;102:611–6.

    Article  CAS  PubMed  Google Scholar 

  5. Piazza G, Goldhaber SZ, Lessard DM, Goldberg RJ, Emery C, Spencer FA. Venous thromboembolism in heart failure: preventable deaths during and after hospitalization. Am J Med. 2011;124:252–9.

    Article  PubMed  Google Scholar 

  6. Khoury H, Welner S, Kubin M, Folkerts K, Haas S. Disease burden and unmet needs for prevention of venous thromboembolism in medically ill patients in europe show underutilisation of preventive therapies. Thromb Haemost. 2011;106:600–8.

    Article  CAS  PubMed  Google Scholar 

  7. Witt BJ, Gami AS, Ballman KV, Brown Jr RD, Meverden RA, Jacobsen SJ, et al. The incidence of ischemic stroke in chronic heart failure: a meta-analysis. J Card Fail. 2007;13:489–96.

    Article  PubMed  Google Scholar 

  8. Appelros P, Nydevik I, Viitanen M. Poor outcome after first-ever stroke: predictors for death, dependency, and recurrent stroke within the first year. Stroke. 2003;34:122–6.

    Article  PubMed  Google Scholar 

  9. Hays AG, Sacco RL, Rundek T, Sciacca RR, Jin Z, Liu R, et al. Left ventricular systolic dysfunction and the risk of ischemic stroke in a multiethnic population. Stroke. 2006;37:1715–9.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Linssen GC, Rienstra M, Jaarsma T, Voors AA, van Gelder IC, Hillege HL, et al. Clinical and prognostic effects of atrial fibrillation in heart failure patients with reduced and preserved left ventricular ejection fraction. Eur J Heart Fail. 2011;13:1111–20.

    Article  PubMed  Google Scholar 

  11. Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the candesartan in heart failure assessment of reduction in mortality and morbidity (charm) program. J Am Coll Cardiol. 2006;47:1997–2004.

    Article  PubMed  Google Scholar 

  12. Carson PE, Johnson GR, Dunkman WB, Fletcher RD, Farrell L, Cohn JN. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The v-heft studies. The v-heft va cooperative studies group. Circulation. 1993;87:VI102–10.

    CAS  PubMed  Google Scholar 

  13. Jang SJ, Kim MS, Park HJ, Han S, Kang DH, Song JK, et al. Impact of heart failure with normal ejection fraction on the occurrence of ischemic stroke in patients with atrial fibrillation. Heart. 2012.

  14. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366:120–9.

    Article  CAS  PubMed  Google Scholar 

  15. Goyal A, Norton CR, Thomas TN, Davis RL, Butler J, Ashok V, et al. Predictors of incident heart failure in a large insured population: a one million person-year follow-up study. Circ Heart Fail. 2010;3:698–705.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Leonard JJ, Shaver J, Thompson M. Left atrial transport function. Trans Am Clin Climatol Assoc. 1981;92:133–41.

    CAS  PubMed Central  PubMed  Google Scholar 

  17. Rahimtoola SH, Ehsani A, Sinno MZ, Loeb HS, Rosen KM, Gunnar RM. Left atrial transport function in myocardial infarction. Importance of its booster pump function. Am J Med. 1975;59:686–94.

    Article  CAS  PubMed  Google Scholar 

  18. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449–57.

    Google Scholar 

  19. Pozzoli M, Cioffi G, Traversi E, Pinna GD, Cobelli F, Tavazzi L. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol. 1998;32:197–204.

    Article  CAS  PubMed  Google Scholar 

  20. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996;61:755–9.

    Article  CAS  PubMed  Google Scholar 

  21. Pollick C, Taylor D. Assessment of left atrial appendage function by transesophageal echocardiography. Implications for the development of thrombus. Circulation. 1991;84:223–31.

    Article  CAS  PubMed  Google Scholar 

  22. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet. 2009;373:155–66.

    Article  CAS  PubMed  Google Scholar 

  23. Sanfilippo AJ, Abascal VM, Sheehan M, Oertel LB, Harrigan P, Hughes RA, et al. Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study. Circulation. 1990;82:792–7.

    Article  CAS  PubMed  Google Scholar 

  24. Predictors of thromboembolism in atrial fibrillation: Ii. Echocardiographic features of patients at risk. The stroke prevention in atrial fibrillation investigators. Ann Intern Med. 1992;116:6–12.

    Google Scholar 

  25. Di Tullio MR, Sacco RL, Sciacca RR, Homma S. Left atrial size and the risk of ischemic stroke in an ethnically mixed population. Stroke. 1999;30:2019–24.

    Article  PubMed  Google Scholar 

  26. Masawa N, Yoshida Y, Yamada T, Joshita T, Ooneda G. Diagnosis of cardiac thrombosis in patients with atrial fibrillation in the absence of macroscopically visible thrombi. Virchows Arch A Pathol Anat Histopathol. 1993;422:67–71.

    Article  CAS  PubMed  Google Scholar 

  27. Marin F, Roldan V, Climent VE, Ibanez A, Garcia A, Marco P, et al. Plasma von willebrand factor, soluble thrombomodulin, and fibrin d-dimer concentrations in acute onset nonrheumatic atrial fibrillation. Heart. 2004;90:1162–6.

    Article  CAS  PubMed  Google Scholar 

  28. Vaduganathan M, Greene SJ, Butler J, Sabbah HN, Shantsila E, Lip GY, et al. The immunological axis in heart failure: importance of the leukocyte differential. Heart Fail Rev. 2013;18(6):835–45.

    Google Scholar 

  29. Chamberlain AM, Redfield MM, Alonso A, Weston SA, Roger VL. Atrial fibrillation and mortality in heart failure: a community study. Circ Heart Fail. 2011;4:740–6.

    Article  PubMed Central  PubMed  Google Scholar 

  30. Santini M, Gasparini M, Landolina M, Lunati M, Proclemer A, Padeletti L, et al. Device-detected atrial tachyarrhythmias predict adverse outcome in real-world patients with implantable biventricular defibrillators. J Am Coll Cardiol. 2011;57:167–72.

    Article  PubMed  Google Scholar 

  31. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (esc). Eur Heart J. 2010;31:2369–429.

    Article  PubMed  Google Scholar 

  32. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the esc guidelines for the management of atrial fibrillation: an update of the 2010 esc guidelines for the management of atrial fibrillation. Developed with the special contribution of the european heart rhythm association. Eur Heart J. 2012;33:2719–47.

    Article  PubMed  Google Scholar 

  33. Mamas MA, Caldwell JC, Chacko S, Garratt CJ, Fath-Ordoubadi F, Neyses L. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail. 2009;11:676–83.

    Article  PubMed  Google Scholar 

  34. Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR, et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med. 2012;366:1859–69. This clinical trial shows that warfarin does not affect the primary outcome of ischemic stroke, intracerebral hemorrhage, or death patients with systolic LV impairment and sinus rhythm.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin k antagonists: the seventh ACCP conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:204S–33S.

    Article  CAS  PubMed  Google Scholar 

  36. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165:1095–106.

    Article  CAS  PubMed  Google Scholar 

  37. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban vs warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91. This paper reports results of the major clinical trial which demonstrated noninferiority of the one daily regimen of factor Xa inhibitor, rivaroxaban compared with warfarin for prevention of stroke and thromboprofilaxix in nonvalvular atrial fibrillation.

    Article  CAS  PubMed  Google Scholar 

  38. Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37:74–81.

    Article  CAS  PubMed  Google Scholar 

  39. Wong PC, Crain EJ, Xin B, Wexler RR, Lam PY, Pinto DJ, et al. Apixaban, an oral, direct and highly selective factor xa inhibitor: in vitro, antithrombotic, and antihemostatic studies. J Thromb Haemost. 2008;6:820–9.

    Article  CAS  PubMed  Google Scholar 

  40. McMurray JJ, Ezekowitz JA, Lewis BS, Gersh BJ, van Diepen S, Amerena J, et al. Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the aristotle trial. Circ Heart Fail. 2013;6:451–60.

    Article  CAS  PubMed  Google Scholar 

  41. Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, et al. N-terminal pro-b-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the aristotle trial (apixaban for the prevention of stroke in subjects with atrial fibrillation). J Am Coll Cardiol. 2013;61:2274–84.

    Article  CAS  PubMed  Google Scholar 

  42. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran vs warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51. This paper reports results of the major clinical trial which assessed effectiveness and safety of dabigatran, an oral direct thrombin inhibitor in patietns with nonvalvular atrial fibrillation.

    Article  CAS  PubMed  Google Scholar 

  43. Mueck W, Eriksson BI, Bauer KA, Borris L, Dahl OE, Fisher WD, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban—an oral, direct factor xa inhibitor—in patients undergoing major orthopaedic surgery. Clin Pharmacokinet. 2008;47:203–16.

    Article  CAS  PubMed  Google Scholar 

  44. Kubitza D, Haas S. Novel factor xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin Investig Drugs. 2006;15:843–55.

    Article  CAS  PubMed  Google Scholar 

  45. Laux V, Perzborn E, Kubitza D, Misselwitz F. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor xa inhibitor. Semin Thromb Hemost. 2007;33:515–23.

    Article  CAS  PubMed  Google Scholar 

  46. Gheorghiade M, Thyssen A, Zolynas R, Nadar VK, Greenberg BH, Mehra M, et al. Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure. J Heart Lung Transplant. 2011;30:218–26.

    Article  PubMed  Google Scholar 

  47. Wu AH, Wang P, Smith A, Haller C, Drake K, Linder M, et al. Dosing algorithm for warfarin using cyp2c9 and vkorc1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics. 2008;9:169–78.

    Article  CAS  PubMed  Google Scholar 

  48. Ferreira J, Ezekowitz MD, Connolly SJ, Brueckmann M, Fraessdorf M, Reilly PA, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial. Eur J Heart Fail. 2013;15:1053–61.

    Article  CAS  PubMed  Google Scholar 

  49. Faxon DP, Eikelboom JW, Berger PB, Holmes DR, Bhatt DL, Moliterno DJ, et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A north-american perspective. Thromb Haemost. 2011;106:572–84.

    Article  CAS  PubMed  Google Scholar 

  50. Huber K, Airaksinen KJ, Cuisset T, Marin F, Rubboli A, Lip GY. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between north america and europe. Thromb Haemost. 2011;106:569–71.

    Article  CAS  PubMed  Google Scholar 

  51. Marinigh R, Lane DA, Lip GY. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol. 2011;57:1339–48.

    Article  PubMed  Google Scholar 

  52. Olesen JB, Lip GY, Kamper AL, Hommel K, Kober L, Lane DA, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367:625–35.

    Article  CAS  PubMed  Google Scholar 

  53. Poli D, Antonucci E, Zanazzi M, Grifoni E, Testa S, Ageno W, et al. Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin k antagonists. Results of epica study on the behalf of fcsa (italian federation of anticoagulation clinics). Thromb Haemost. 2012;107:1100–6.

    Article  CAS  PubMed  Google Scholar 

  54. Roldan V, Marin F, Manzano-Fernandez S, Fernandez H, Gallego P, Valdes M, et al. Does chronic kidney disease improve the predictive value of the chads2 and cha2ds2-vasc stroke stratification risk scores for atrial fibrillation? Thromb Haemost. 2013;109:956–60.

    Article  CAS  PubMed  Google Scholar 

  55. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban vs warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92. This paper reports results of the major clinical trial which demonstrated superior effectiveness and safety of a factor Xa inhibitor, apixaban compared with warfarin in nonvalvular atrial fibrillation.

    Article  CAS  PubMed  Google Scholar 

  56. van Diepen S, Hellkamp AS, Patel MR, Becker RC, Breithardt G, Hacke W, et al. Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from rocket af. Circ Heart Fail. 2013;6:740–7.

    Article  PubMed  Google Scholar 

  57. Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost. 2012;107:838–47.

    Article  CAS  PubMed  Google Scholar 

  58. Turpie AG, Kreutz R, Llau J, Norrving B, Haas S. Management consensus guidance for the use of rivaroxaban - an oral, direct factor xa inhibitor. Thromb Haemost. 2012;108:876–86.

    Article  CAS  PubMed  Google Scholar 

  59. Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Palareti G, et al. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the italian federation of thrombosis centers (fcsa). Thromb Haemost. 2011;106:868–76.

    Article  CAS  PubMed  Google Scholar 

  60. Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control amongst atrial fibrillation patients on warfarin:The same-tt2r2 (sex female, age less than 60, medical history, treatment strategy [rhythm control], tobacco use [doubled], race [doubled] score. Chest. 2013;144(5):1555–63.

  61. Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost. 2011;106:968–77.

    Article  CAS  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Dr. Eduard Shantsila declares no potential conflicts of interest relevant to this article. Dr. Gregory Y. H. Lip has served as a consultant for Bayer, Astellas, Merck, AstraZeneca, Sanofi, BMS/Pfizer, Biotronik, Portola, and Boehringer Ingelheim and has been on the speaker’s bureau for Bayer, BMS/Pfizer, Boehringer Ingelheim, and Sanofi-Aventis.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. University of Birmingham Center for Cardiovascular Sciences, City Hospital, Birmingham, B18 7QH, UK

    Eduard Shantsila PhD & Gregory Y.H. Lip MD

Authors
  1. Eduard Shantsila PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gregory Y.H. Lip MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gregory Y.H. Lip MD.

Additional information

This article is part of the Topical Collection on Heart Failure

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shantsila, E., Lip, G.Y. Use of Novel Oral Anticoagulants in Patients With Heart Failure. Curr Treat Options Cardio Med 16, 285 (2014). https://doi.org/10.1007/s11936-013-0285-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11936-013-0285-y

Keywords

Search

Navigation